Abbott Labs Deserves Its Premium

Abbott Laboratories (ABT - Analyst Report) discovers, develops, manufactures and sells a diversified line of healthcare products. We expect double-digit EPS growth over the next few years driven by strong sales of Humira and the company's rapidly growing vascular business.

Several new drug applications have recently been filed with the FDA which should accelerate sales in the pharmaceutical business. Based on our model, the company is expected to deliver high single-digit EPS growth through the end of 2013.

We believe ABT possesses a low-risk profile and will continue to trade at an industry premium. Accordingly, we reiterate our Buy recommendation with a price target of $65.

Jason Napodano, CFA contributed to this report.

Read the full analyst report on ABT